Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Glaukos Corp has demonstrated strong financial performance, reporting glaucoma revenue of $110 million in 3Q25, which surpassed consensus estimates and reflected a robust growth rate of 45% compared to prior quarters. The company's domestic glaucoma revenue reached $81 million, indicating a significant year-over-year increase of 57% and contributing to an improved operating margin of (7.0%), marking a notable recovery from previous periods. Additionally, Glaukos's Corneal Health segment has shown impressive growth with a compound annual growth rate of approximately 15.2% globally, further highlighting the company's positive trajectory and potential for future expansion within the ophthalmic market.

Bears say

Glaukos Corp's financial outlook is negatively affected by several factors, including a notable decline in legacy surgical glaucoma revenue, which decreased by 4.7% to $40.8 million, signaling potential stagnation in product demand. Additionally, anticipated decreases in Epioxa volumes and challenges in the Corneal Health segment suggest further material declines year-over-year, driven by a transitional phase in product adoption and reimbursement issues. Moreover, the company faces risks from slower-than-expected market growth for minimally invasive glaucoma surgery (MIGS) products, decreased uptake of its innovative iDose product, and heightened competition from new market entrants.

Glaukos (GKOS) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 13 analysts, Glaukos (GKOS) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $126.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $126.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.